nodes	percent_of_prediction	percent_of_DWPC	metapath
Trihexyphenidyl—Cloperastine—Raloxifene—osteoporosis	0.82	1	CrCrCtD
Trihexyphenidyl—Chorea—Estropipate—osteoporosis	0.0156	0.0954	CcSEcCtD
Trihexyphenidyl—Chorea—Conjugated Estrogens—osteoporosis	0.0103	0.0631	CcSEcCtD
Trihexyphenidyl—Chorea—Estradiol—osteoporosis	0.00823	0.0505	CcSEcCtD
Trihexyphenidyl—Blindness—Estradiol—osteoporosis	0.00312	0.0191	CcSEcCtD
Trihexyphenidyl—Weight decreased—Ergocalciferol—osteoporosis	0.00288	0.0177	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Calcitriol—osteoporosis	0.00217	0.0133	CcSEcCtD
Trihexyphenidyl—Dry skin—Alendronate—osteoporosis	0.00214	0.0131	CcSEcCtD
Trihexyphenidyl—Confusional state—Calcium Acetate—osteoporosis	0.00207	0.0127	CcSEcCtD
Trihexyphenidyl—Hallucination—Etidronic acid—osteoporosis	0.00188	0.0116	CcSEcCtD
Trihexyphenidyl—Weight decreased—Ibandronate—osteoporosis	0.00178	0.0109	CcSEcCtD
Trihexyphenidyl—Constipation—Calcium Acetate—osteoporosis	0.00175	0.0107	CcSEcCtD
Trihexyphenidyl—Weight decreased—Calcitriol—osteoporosis	0.00174	0.0107	CcSEcCtD
Trihexyphenidyl—Psychotic disorder—Pamidronate—osteoporosis	0.00174	0.0107	CcSEcCtD
Trihexyphenidyl—Drowsiness—Calcitriol—osteoporosis	0.00171	0.0105	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Calcium Acetate—osteoporosis	0.00169	0.0104	CcSEcCtD
Trihexyphenidyl—Constipation—Ergocalciferol—osteoporosis	0.00155	0.00949	CcSEcCtD
Trihexyphenidyl—Weight decreased—Ethinyl Estradiol—osteoporosis	0.0015	0.0092	CcSEcCtD
Trihexyphenidyl—Asthenia—Calcium Acetate—osteoporosis	0.00147	0.00901	CcSEcCtD
Trihexyphenidyl—Tension—Estropipate—osteoporosis	0.0014	0.00858	CcSEcCtD
Trihexyphenidyl—Nervousness—Estropipate—osteoporosis	0.00138	0.00849	CcSEcCtD
Trihexyphenidyl—Confusional state—Etidronic acid—osteoporosis	0.00136	0.00832	CcSEcCtD
Trihexyphenidyl—Dizziness—Calcium Acetate—osteoporosis	0.00135	0.00831	CcSEcCtD
Trihexyphenidyl—Vomiting—Calcium Acetate—osteoporosis	0.0013	0.00799	CcSEcCtD
Trihexyphenidyl—Asthenia—Ergocalciferol—osteoporosis	0.0013	0.00796	CcSEcCtD
Trihexyphenidyl—Weight decreased—Zoledronate—osteoporosis	0.00127	0.00779	CcSEcCtD
Trihexyphenidyl—Agitation—Calcitriol—osteoporosis	0.00123	0.00754	CcSEcCtD
Trihexyphenidyl—Nausea—Calcium Acetate—osteoporosis	0.00122	0.00746	CcSEcCtD
Trihexyphenidyl—Constipation—Etidronic acid—osteoporosis	0.00115	0.00705	CcSEcCtD
Trihexyphenidyl—Dry skin—Estradiol—osteoporosis	0.00115	0.00704	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Etidronic acid—osteoporosis	0.00111	0.0068	CcSEcCtD
Trihexyphenidyl—Nausea—Ergocalciferol—osteoporosis	0.00108	0.00659	CcSEcCtD
Trihexyphenidyl—Tension—Pamidronate—osteoporosis	0.00105	0.00645	CcSEcCtD
Trihexyphenidyl—Nervousness—Pamidronate—osteoporosis	0.00104	0.00638	CcSEcCtD
Trihexyphenidyl—Somnolence—Estropipate—osteoporosis	0.00103	0.00634	CcSEcCtD
Trihexyphenidyl—Constipation—Estropipate—osteoporosis	0.000995	0.0061	CcSEcCtD
Trihexyphenidyl—Agitation—Pamidronate—osteoporosis	0.000984	0.00604	CcSEcCtD
Trihexyphenidyl—Constipation—Alendronate—osteoporosis	0.00098	0.00601	CcSEcCtD
Trihexyphenidyl—Weight decreased—Estradiol—osteoporosis	0.000979	0.006	CcSEcCtD
Trihexyphenidyl—Somnolence—Calcitriol—osteoporosis	0.000971	0.00595	CcSEcCtD
Trihexyphenidyl—Constipation—Ibandronate—osteoporosis	0.000954	0.00585	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Alendronate—osteoporosis	0.000944	0.00579	CcSEcCtD
Trihexyphenidyl—Constipation—Calcitriol—osteoporosis	0.000934	0.00573	CcSEcCtD
Trihexyphenidyl—Tension—Conjugated Estrogens—osteoporosis	0.000925	0.00567	CcSEcCtD
Trihexyphenidyl—Vision blurred—Zoledronate—osteoporosis	0.000922	0.00565	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Ibandronate—osteoporosis	0.00092	0.00564	CcSEcCtD
Trihexyphenidyl—Nervousness—Conjugated Estrogens—osteoporosis	0.000915	0.00561	CcSEcCtD
Trihexyphenidyl—Agitation—Zoledronate—osteoporosis	0.000899	0.00551	CcSEcCtD
Trihexyphenidyl—Vision blurred—Conjugated Estrogens—osteoporosis	0.000888	0.00544	CcSEcCtD
Trihexyphenidyl—Confusional state—Pamidronate—osteoporosis	0.000881	0.00541	CcSEcCtD
Trihexyphenidyl—Vomiting—Etidronic acid—osteoporosis	0.000855	0.00524	CcSEcCtD
Trihexyphenidyl—Tachycardia—Pamidronate—osteoporosis	0.000853	0.00523	CcSEcCtD
Trihexyphenidyl—Rash—Etidronic acid—osteoporosis	0.000848	0.0052	CcSEcCtD
Trihexyphenidyl—Dermatitis—Etidronic acid—osteoporosis	0.000847	0.0052	CcSEcCtD
Trihexyphenidyl—Headache—Etidronic acid—osteoporosis	0.000843	0.00517	CcSEcCtD
Trihexyphenidyl—Asthenia—Estropipate—osteoporosis	0.000835	0.00512	CcSEcCtD
Trihexyphenidyl—Asthenia—Alendronate—osteoporosis	0.000822	0.00504	CcSEcCtD
Trihexyphenidyl—Constipation—Ethinyl Estradiol—osteoporosis	0.000807	0.00495	CcSEcCtD
Trihexyphenidyl—Confusional state—Zoledronate—osteoporosis	0.000805	0.00494	CcSEcCtD
Trihexyphenidyl—Asthenia—Ibandronate—osteoporosis	0.000801	0.00491	CcSEcCtD
Trihexyphenidyl—Nausea—Etidronic acid—osteoporosis	0.000799	0.0049	CcSEcCtD
Trihexyphenidyl—Constipation—Risedronate—osteoporosis	0.000786	0.00482	CcSEcCtD
Trihexyphenidyl—Asthenia—Calcitriol—osteoporosis	0.000784	0.00481	CcSEcCtD
Trihexyphenidyl—Tachycardia—Zoledronate—osteoporosis	0.000779	0.00478	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000777	0.00477	CcSEcCtD
Trihexyphenidyl—Somnolence—Pamidronate—osteoporosis	0.000777	0.00477	CcSEcCtD
Trihexyphenidyl—Dizziness—Estropipate—osteoporosis	0.00077	0.00472	CcSEcCtD
Trihexyphenidyl—Dizziness—Alendronate—osteoporosis	0.000758	0.00465	CcSEcCtD
Trihexyphenidyl—Tachycardia—Conjugated Estrogens—osteoporosis	0.00075	0.0046	CcSEcCtD
Trihexyphenidyl—Constipation—Pamidronate—osteoporosis	0.000748	0.00458	CcSEcCtD
Trihexyphenidyl—Dizziness—Raloxifene—osteoporosis	0.000745	0.00457	CcSEcCtD
Trihexyphenidyl—Tension—Estradiol—osteoporosis	0.00074	0.00454	CcSEcCtD
Trihexyphenidyl—Vomiting—Estropipate—osteoporosis	0.00074	0.00454	CcSEcCtD
Trihexyphenidyl—Dizziness—Ibandronate—osteoporosis	0.000738	0.00452	CcSEcCtD
Trihexyphenidyl—Rash—Estropipate—osteoporosis	0.000734	0.0045	CcSEcCtD
Trihexyphenidyl—Dermatitis—Estropipate—osteoporosis	0.000733	0.00449	CcSEcCtD
Trihexyphenidyl—Nervousness—Estradiol—osteoporosis	0.000732	0.00449	CcSEcCtD
Trihexyphenidyl—Headache—Estropipate—osteoporosis	0.000729	0.00447	CcSEcCtD
Trihexyphenidyl—Vomiting—Alendronate—osteoporosis	0.000729	0.00447	CcSEcCtD
Trihexyphenidyl—Rash—Alendronate—osteoporosis	0.000723	0.00443	CcSEcCtD
Trihexyphenidyl—Dermatitis—Alendronate—osteoporosis	0.000722	0.00443	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Pamidronate—osteoporosis	0.00072	0.00442	CcSEcCtD
Trihexyphenidyl—Headache—Alendronate—osteoporosis	0.000718	0.0044	CcSEcCtD
Trihexyphenidyl—Vomiting—Raloxifene—osteoporosis	0.000717	0.00439	CcSEcCtD
Trihexyphenidyl—Rash—Raloxifene—osteoporosis	0.000711	0.00436	CcSEcCtD
Trihexyphenidyl—Dermatitis—Raloxifene—osteoporosis	0.00071	0.00435	CcSEcCtD
Trihexyphenidyl—Somnolence—Zoledronate—osteoporosis	0.00071	0.00435	CcSEcCtD
Trihexyphenidyl—Vomiting—Ibandronate—osteoporosis	0.00071	0.00435	CcSEcCtD
Trihexyphenidyl—Headache—Raloxifene—osteoporosis	0.000706	0.00433	CcSEcCtD
Trihexyphenidyl—Rash—Ibandronate—osteoporosis	0.000704	0.00431	CcSEcCtD
Trihexyphenidyl—Dermatitis—Ibandronate—osteoporosis	0.000703	0.00431	CcSEcCtD
Trihexyphenidyl—Headache—Ibandronate—osteoporosis	0.000699	0.00429	CcSEcCtD
Trihexyphenidyl—Vomiting—Calcitriol—osteoporosis	0.000695	0.00426	CcSEcCtD
Trihexyphenidyl—Agitation—Estradiol—osteoporosis	0.000693	0.00425	CcSEcCtD
Trihexyphenidyl—Nausea—Estropipate—osteoporosis	0.000691	0.00424	CcSEcCtD
Trihexyphenidyl—Rash—Calcitriol—osteoporosis	0.000689	0.00422	CcSEcCtD
Trihexyphenidyl—Dermatitis—Calcitriol—osteoporosis	0.000688	0.00422	CcSEcCtD
Trihexyphenidyl—Headache—Calcitriol—osteoporosis	0.000684	0.0042	CcSEcCtD
Trihexyphenidyl—Somnolence—Conjugated Estrogens—osteoporosis	0.000684	0.00419	CcSEcCtD
Trihexyphenidyl—Constipation—Zoledronate—osteoporosis	0.000683	0.00419	CcSEcCtD
Trihexyphenidyl—Nausea—Alendronate—osteoporosis	0.000681	0.00417	CcSEcCtD
Trihexyphenidyl—Asthenia—Ethinyl Estradiol—osteoporosis	0.000677	0.00415	CcSEcCtD
Trihexyphenidyl—Nausea—Raloxifene—osteoporosis	0.00067	0.00411	CcSEcCtD
Trihexyphenidyl—Nausea—Ibandronate—osteoporosis	0.000663	0.00406	CcSEcCtD
Trihexyphenidyl—Asthenia—Risedronate—osteoporosis	0.00066	0.00405	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Zoledronate—osteoporosis	0.000658	0.00404	CcSEcCtD
Trihexyphenidyl—Constipation—Conjugated Estrogens—osteoporosis	0.000658	0.00403	CcSEcCtD
Trihexyphenidyl—Nausea—Calcitriol—osteoporosis	0.000649	0.00398	CcSEcCtD
Trihexyphenidyl—Asthenia—Pamidronate—osteoporosis	0.000627	0.00385	CcSEcCtD
Trihexyphenidyl—Dizziness—Ethinyl Estradiol—osteoporosis	0.000624	0.00382	CcSEcCtD
Trihexyphenidyl—Confusional state—Estradiol—osteoporosis	0.00062	0.0038	CcSEcCtD
Trihexyphenidyl—Dizziness—Risedronate—osteoporosis	0.000608	0.00373	CcSEcCtD
Trihexyphenidyl—Tachycardia—Estradiol—osteoporosis	0.000601	0.00368	CcSEcCtD
Trihexyphenidyl—Vomiting—Ethinyl Estradiol—osteoporosis	0.0006	0.00368	CcSEcCtD
Trihexyphenidyl—Rash—Ethinyl Estradiol—osteoporosis	0.000595	0.00365	CcSEcCtD
Trihexyphenidyl—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000594	0.00364	CcSEcCtD
Trihexyphenidyl—Headache—Ethinyl Estradiol—osteoporosis	0.000591	0.00362	CcSEcCtD
Trihexyphenidyl—Vomiting—Risedronate—osteoporosis	0.000585	0.00359	CcSEcCtD
Trihexyphenidyl—Rash—Risedronate—osteoporosis	0.00058	0.00356	CcSEcCtD
Trihexyphenidyl—Dermatitis—Risedronate—osteoporosis	0.000579	0.00355	CcSEcCtD
Trihexyphenidyl—Dizziness—Pamidronate—osteoporosis	0.000578	0.00354	CcSEcCtD
Trihexyphenidyl—Headache—Risedronate—osteoporosis	0.000576	0.00353	CcSEcCtD
Trihexyphenidyl—Asthenia—Zoledronate—osteoporosis	0.000573	0.00351	CcSEcCtD
Trihexyphenidyl—Nausea—Ethinyl Estradiol—osteoporosis	0.00056	0.00344	CcSEcCtD
Trihexyphenidyl—Vomiting—Pamidronate—osteoporosis	0.000556	0.00341	CcSEcCtD
Trihexyphenidyl—Asthenia—Conjugated Estrogens—osteoporosis	0.000552	0.00338	CcSEcCtD
Trihexyphenidyl—Rash—Pamidronate—osteoporosis	0.000551	0.00338	CcSEcCtD
Trihexyphenidyl—Dermatitis—Pamidronate—osteoporosis	0.000551	0.00338	CcSEcCtD
Trihexyphenidyl—Headache—Pamidronate—osteoporosis	0.000548	0.00336	CcSEcCtD
Trihexyphenidyl—Somnolence—Estradiol—osteoporosis	0.000547	0.00335	CcSEcCtD
Trihexyphenidyl—Nausea—Risedronate—osteoporosis	0.000546	0.00335	CcSEcCtD
Trihexyphenidyl—Dizziness—Zoledronate—osteoporosis	0.000528	0.00324	CcSEcCtD
Trihexyphenidyl—Constipation—Estradiol—osteoporosis	0.000526	0.00323	CcSEcCtD
Trihexyphenidyl—Nausea—Pamidronate—osteoporosis	0.000519	0.00318	CcSEcCtD
Trihexyphenidyl—Dizziness—Conjugated Estrogens—osteoporosis	0.000508	0.00312	CcSEcCtD
Trihexyphenidyl—Vomiting—Zoledronate—osteoporosis	0.000508	0.00311	CcSEcCtD
Trihexyphenidyl—Feeling abnormal—Estradiol—osteoporosis	0.000507	0.00311	CcSEcCtD
Trihexyphenidyl—Rash—Zoledronate—osteoporosis	0.000503	0.00309	CcSEcCtD
Trihexyphenidyl—Dermatitis—Zoledronate—osteoporosis	0.000503	0.00308	CcSEcCtD
Trihexyphenidyl—Headache—Zoledronate—osteoporosis	0.0005	0.00307	CcSEcCtD
Trihexyphenidyl—Vomiting—Conjugated Estrogens—osteoporosis	0.000489	0.003	CcSEcCtD
Trihexyphenidyl—Rash—Conjugated Estrogens—osteoporosis	0.000485	0.00297	CcSEcCtD
Trihexyphenidyl—Dermatitis—Conjugated Estrogens—osteoporosis	0.000484	0.00297	CcSEcCtD
Trihexyphenidyl—Headache—Conjugated Estrogens—osteoporosis	0.000482	0.00295	CcSEcCtD
Trihexyphenidyl—Nausea—Zoledronate—osteoporosis	0.000474	0.00291	CcSEcCtD
Trihexyphenidyl—Nausea—Conjugated Estrogens—osteoporosis	0.000457	0.0028	CcSEcCtD
Trihexyphenidyl—Asthenia—Estradiol—osteoporosis	0.000442	0.00271	CcSEcCtD
Trihexyphenidyl—Dizziness—Estradiol—osteoporosis	0.000407	0.0025	CcSEcCtD
Trihexyphenidyl—Vomiting—Estradiol—osteoporosis	0.000391	0.0024	CcSEcCtD
Trihexyphenidyl—Rash—Estradiol—osteoporosis	0.000388	0.00238	CcSEcCtD
Trihexyphenidyl—Dermatitis—Estradiol—osteoporosis	0.000388	0.00238	CcSEcCtD
Trihexyphenidyl—Headache—Estradiol—osteoporosis	0.000386	0.00236	CcSEcCtD
Trihexyphenidyl—Nausea—Estradiol—osteoporosis	0.000366	0.00224	CcSEcCtD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—CALCA—osteoporosis	3.27e-05	0.00192	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—LRP6—osteoporosis	3.25e-05	0.00191	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—PTHLH—osteoporosis	3.23e-05	0.0019	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—CALCA—osteoporosis	3.13e-05	0.00184	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CALCR—osteoporosis	3.09e-05	0.00182	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PTH1R—osteoporosis	3.09e-05	0.00182	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PTH1R—osteoporosis	3.08e-05	0.00181	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CALCR—osteoporosis	3.08e-05	0.00181	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PTH1R—osteoporosis	3.05e-05	0.00179	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CALCR—osteoporosis	3.05e-05	0.00179	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR ligand binding—POMC—osteoporosis	3.03e-05	0.00178	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—PTH—osteoporosis	3.02e-05	0.00178	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—PTH—osteoporosis	3.01e-05	0.00177	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—OXCT1—osteoporosis	3e-05	0.00176	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—CA2—osteoporosis	3e-05	0.00176	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—PTH—osteoporosis	2.98e-05	0.00176	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—CALCA—osteoporosis	2.97e-05	0.00175	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—CNR2—osteoporosis	2.94e-05	0.00173	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—CNR2—osteoporosis	2.93e-05	0.00173	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—MGLL—osteoporosis	2.92e-05	0.00172	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—CNR2—osteoporosis	2.91e-05	0.00171	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR ligand binding—POMC—osteoporosis	2.9e-05	0.00171	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TLN1—osteoporosis	2.87e-05	0.00169	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—CALCA—osteoporosis	2.84e-05	0.00167	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TLN1—osteoporosis	2.74e-05	0.00162	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—PTH—osteoporosis	2.74e-05	0.00161	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—PTH—osteoporosis	2.73e-05	0.00161	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—PTH—osteoporosis	2.71e-05	0.00159	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	2.68e-05	0.00158	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CNR2—osteoporosis	2.67e-05	0.00157	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	2.67e-05	0.00157	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CNR2—osteoporosis	2.66e-05	0.00157	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	2.64e-05	0.00156	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CNR2—osteoporosis	2.64e-05	0.00155	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—WNT1—osteoporosis	2.51e-05	0.00148	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—WNT1—osteoporosis	2.51e-05	0.00147	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—PTHLH—osteoporosis	2.5e-05	0.00147	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—PTHLH—osteoporosis	2.5e-05	0.00147	CbGpPWpGaD
Trihexyphenidyl—CHRM2—SIDS Susceptibility Pathways—TNF—osteoporosis	2.49e-05	0.00146	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—IDH2—osteoporosis	2.48e-05	0.00146	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—WNT1—osteoporosis	2.48e-05	0.00146	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—PTHLH—osteoporosis	2.47e-05	0.00145	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—P4HB—osteoporosis	2.47e-05	0.00145	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MGLL—osteoporosis	2.45e-05	0.00144	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MGLL—osteoporosis	2.44e-05	0.00144	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MGLL—osteoporosis	2.42e-05	0.00142	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PTH—osteoporosis	2.4e-05	0.00141	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—LRP5—osteoporosis	2.39e-05	0.00141	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—LRP5—osteoporosis	2.38e-05	0.0014	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—P4HB—osteoporosis	2.37e-05	0.00139	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—RAP1A—osteoporosis	2.36e-05	0.00139	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—LRP5—osteoporosis	2.36e-05	0.00139	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CNR2—osteoporosis	2.34e-05	0.00138	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—CYP27A1—osteoporosis	2.34e-05	0.00137	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—ADCY5—osteoporosis	2.32e-05	0.00137	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—NFATC1—osteoporosis	2.3e-05	0.00136	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PTH—osteoporosis	2.3e-05	0.00135	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—LRP6—osteoporosis	2.29e-05	0.00135	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—DKK1—osteoporosis	2.29e-05	0.00135	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—LRP6—osteoporosis	2.28e-05	0.00134	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—PTHLH—osteoporosis	2.27e-05	0.00134	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—ACP5—osteoporosis	2.27e-05	0.00134	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—PTHLH—osteoporosis	2.27e-05	0.00133	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—RAP1A—osteoporosis	2.26e-05	0.00133	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—LRP6—osteoporosis	2.26e-05	0.00133	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—PTHLH—osteoporosis	2.24e-05	0.00132	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CNR2—osteoporosis	2.24e-05	0.00132	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.23e-05	0.00131	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—ADCY5—osteoporosis	2.23e-05	0.00131	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—NFATC1—osteoporosis	2.21e-05	0.0013	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—CALCA—osteoporosis	2.2e-05	0.0013	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—WNT1—osteoporosis	2.2e-05	0.0013	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—CALCA—osteoporosis	2.2e-05	0.00129	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—DKK1—osteoporosis	2.19e-05	0.00129	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—CALCA—osteoporosis	2.18e-05	0.00128	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—FGA—osteoporosis	2.14e-05	0.00126	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—TPI1—osteoporosis	2.11e-05	0.00124	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—ADCY5—osteoporosis	2.11e-05	0.00124	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—WNT1—osteoporosis	2.11e-05	0.00124	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—FGA—osteoporosis	2.05e-05	0.00121	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR ligand binding—POMC—osteoporosis	2.04e-05	0.0012	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR ligand binding—POMC—osteoporosis	2.03e-05	0.0012	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—ADCY5—osteoporosis	2.02e-05	0.00119	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR ligand binding—POMC—osteoporosis	2.01e-05	0.00119	CbGpPWpGaD
Trihexyphenidyl—CHRM2—SIDS Susceptibility Pathways—IL6—osteoporosis	2.01e-05	0.00118	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—CALCA—osteoporosis	2e-05	0.00118	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—CALCA—osteoporosis	1.99e-05	0.00117	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PTHLH—osteoporosis	1.99e-05	0.00117	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—BMP2—osteoporosis	1.99e-05	0.00117	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—P4HB—osteoporosis	1.99e-05	0.00117	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—CALCA—osteoporosis	1.98e-05	0.00116	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—GAPDH—osteoporosis	1.95e-05	0.00115	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—FGB—osteoporosis	1.95e-05	0.00115	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TLN1—osteoporosis	1.93e-05	0.00114	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TLN1—osteoporosis	1.93e-05	0.00113	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—BMP2—osteoporosis	1.91e-05	0.00112	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PTHLH—osteoporosis	1.91e-05	0.00112	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TLN1—osteoporosis	1.91e-05	0.00112	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—RAP1A—osteoporosis	1.9e-05	0.00112	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PSMA2—osteoporosis	1.88e-05	0.00111	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—PSMA5—osteoporosis	1.88e-05	0.00111	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—FGB—osteoporosis	1.87e-05	0.0011	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PSMA2—osteoporosis	1.8e-05	0.00106	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—PSMA5—osteoporosis	1.8e-05	0.00106	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—CALCA—osteoporosis	1.75e-05	0.00103	CbGpPWpGaD
Trihexyphenidyl—CHRM4—GPCR downstream signaling—POMC—osteoporosis	1.71e-05	0.00101	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—CALCA—osteoporosis	1.68e-05	0.000988	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—P4HB—osteoporosis	1.67e-05	0.000981	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—P4HB—osteoporosis	1.66e-05	0.000977	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Circadian rythm related genes—IL6—osteoporosis	1.66e-05	0.000977	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—P4HB—osteoporosis	1.64e-05	0.000968	CbGpPWpGaD
Trihexyphenidyl—CHRM5—GPCR downstream signaling—POMC—osteoporosis	1.64e-05	0.000964	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PTH—osteoporosis	1.62e-05	0.000954	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PTH—osteoporosis	1.62e-05	0.000951	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PTH—osteoporosis	1.6e-05	0.000942	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—RAP1A—osteoporosis	1.59e-05	0.000937	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—KL—osteoporosis	1.59e-05	0.000937	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—RAP1A—osteoporosis	1.59e-05	0.000934	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CNR2—osteoporosis	1.58e-05	0.00093	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CNR2—osteoporosis	1.57e-05	0.000927	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	1.57e-05	0.000925	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—RAP1A—osteoporosis	1.57e-05	0.000925	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—ADCY5—osteoporosis	1.57e-05	0.000923	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	1.57e-05	0.000923	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—ADCY5—osteoporosis	1.56e-05	0.00092	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CNR2—osteoporosis	1.56e-05	0.000918	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—NFATC1—osteoporosis	1.55e-05	0.000915	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—POMC—osteoporosis	1.55e-05	0.000914	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—NFATC1—osteoporosis	1.55e-05	0.000912	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—ADCY5—osteoporosis	1.55e-05	0.000911	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—DKK1—osteoporosis	1.54e-05	0.000907	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—DKK1—osteoporosis	1.54e-05	0.000904	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—ENO1—osteoporosis	1.53e-05	0.000903	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—NFATC1—osteoporosis	1.53e-05	0.000903	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—KL—osteoporosis	1.52e-05	0.000897	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—DKK1—osteoporosis	1.52e-05	0.000896	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—IL6R—osteoporosis	1.51e-05	0.000892	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PSMA2—osteoporosis	1.51e-05	0.00089	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—PSMA5—osteoporosis	1.51e-05	0.00089	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—POMC—osteoporosis	1.49e-05	0.000875	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—WNT1—osteoporosis	1.48e-05	0.000874	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—WNT1—osteoporosis	1.48e-05	0.000871	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—WNT1—osteoporosis	1.47e-05	0.000863	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—IL6R—osteoporosis	1.45e-05	0.000854	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—FGA—osteoporosis	1.44e-05	0.00085	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—FGA—osteoporosis	1.44e-05	0.000847	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—FGA—osteoporosis	1.43e-05	0.000839	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—ADCY5—osteoporosis	1.42e-05	0.000838	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—ADCY5—osteoporosis	1.42e-05	0.000835	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—ADCY5—osteoporosis	1.41e-05	0.000827	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—BMP2—osteoporosis	1.34e-05	0.00079	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PTHLH—osteoporosis	1.34e-05	0.00079	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—BMP2—osteoporosis	1.34e-05	0.000788	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PTHLH—osteoporosis	1.34e-05	0.000788	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PTHLH—osteoporosis	1.33e-05	0.00078	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—BMP2—osteoporosis	1.33e-05	0.00078	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—FGB—osteoporosis	1.31e-05	0.000773	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—FGB—osteoporosis	1.31e-05	0.000771	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—FGB—osteoporosis	1.3e-05	0.000764	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PSMA5—osteoporosis	1.27e-05	0.000747	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—PSMA2—osteoporosis	1.27e-05	0.000747	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PSMA2—osteoporosis	1.26e-05	0.000744	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—PSMA5—osteoporosis	1.26e-05	0.000744	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PSMA2—osteoporosis	1.25e-05	0.000737	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—PSMA5—osteoporosis	1.25e-05	0.000737	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—ADCY5—osteoporosis	1.25e-05	0.000734	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—CYP19A1—osteoporosis	1.23e-05	0.000722	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—SPP1—osteoporosis	1.21e-05	0.00071	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—ADCY5—osteoporosis	1.19e-05	0.000703	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—CALCA—osteoporosis	1.18e-05	0.000696	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—CALCA—osteoporosis	1.18e-05	0.000694	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—CALCA—osteoporosis	1.17e-05	0.000687	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—SPP1—osteoporosis	1.16e-05	0.00068	CbGpPWpGaD
Trihexyphenidyl—CHRM1—GPCR downstream signaling—POMC—osteoporosis	1.15e-05	0.000679	CbGpPWpGaD
Trihexyphenidyl—CHRM3—GPCR downstream signaling—POMC—osteoporosis	1.15e-05	0.000677	CbGpPWpGaD
Trihexyphenidyl—CHRM2—GPCR downstream signaling—POMC—osteoporosis	1.14e-05	0.00067	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IRS2—osteoporosis	1.09e-05	0.000642	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—KL—osteoporosis	1.07e-05	0.000632	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—KL—osteoporosis	1.07e-05	0.00063	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—LEP—osteoporosis	1.07e-05	0.000629	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—KL—osteoporosis	1.06e-05	0.000624	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—POMC—osteoporosis	1.05e-05	0.000616	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IRS2—osteoporosis	1.04e-05	0.000615	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—POMC—osteoporosis	1.04e-05	0.000614	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—POMC—osteoporosis	1.03e-05	0.000608	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—LEP—osteoporosis	1.02e-05	0.000602	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—IL6R—osteoporosis	1.02e-05	0.000601	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—ESR1—osteoporosis	1.02e-05	0.0006	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—IL6R—osteoporosis	1.02e-05	0.000599	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—IL6R—osteoporosis	1.01e-05	0.000593	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—ADCY5—osteoporosis	1e-05	0.00059	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—GPX1—osteoporosis	9.99e-06	0.000588	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—ESR1—osteoporosis	9.76e-06	0.000575	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IRS1—osteoporosis	9.53e-06	0.000561	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—MTHFR—osteoporosis	9.22e-06	0.000543	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—POMC—osteoporosis	9.17e-06	0.00054	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IRS1—osteoporosis	9.12e-06	0.000537	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL6R—osteoporosis	8.95e-06	0.000527	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IGF1—osteoporosis	8.82e-06	0.000519	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—POMC—osteoporosis	8.78e-06	0.000517	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL6R—osteoporosis	8.57e-06	0.000504	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IGF1—osteoporosis	8.45e-06	0.000497	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—ADCY5—osteoporosis	8.41e-06	0.000495	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ADCY5—osteoporosis	8.38e-06	0.000493	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ADCY5—osteoporosis	8.3e-06	0.000489	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—SPP1—osteoporosis	8.14e-06	0.000479	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—SPP1—osteoporosis	8.11e-06	0.000477	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—SPP1—osteoporosis	8.03e-06	0.000473	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Metabolism—POMC—osteoporosis	7.37e-06	0.000434	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IRS2—osteoporosis	7.36e-06	0.000433	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IRS2—osteoporosis	7.33e-06	0.000432	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IRS2—osteoporosis	7.26e-06	0.000427	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—LEP—osteoporosis	7.2e-06	0.000424	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—LEP—osteoporosis	7.18e-06	0.000422	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—LEP—osteoporosis	7.11e-06	0.000418	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—ESR1—osteoporosis	6.87e-06	0.000405	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—ESR1—osteoporosis	6.85e-06	0.000403	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—ESR1—osteoporosis	6.79e-06	0.000399	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling by GPCR—IL6—osteoporosis	6.75e-06	0.000397	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling by GPCR—IL6—osteoporosis	6.46e-06	0.00038	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IRS1—osteoporosis	6.42e-06	0.000378	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IRS1—osteoporosis	6.4e-06	0.000377	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IRS1—osteoporosis	6.34e-06	0.000373	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—POMC—osteoporosis	6.19e-06	0.000364	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—POMC—osteoporosis	6.17e-06	0.000363	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—POMC—osteoporosis	6.11e-06	0.000359	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL6R—osteoporosis	6.03e-06	0.000355	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL6R—osteoporosis	6.01e-06	0.000354	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL6R—osteoporosis	5.96e-06	0.000351	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IGF1—osteoporosis	5.95e-06	0.00035	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IGF1—osteoporosis	5.93e-06	0.000349	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IGF1—osteoporosis	5.87e-06	0.000346	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—MYC—osteoporosis	5.3e-06	0.000312	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—TGFB1—osteoporosis	5.29e-06	0.000311	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—MYC—osteoporosis	5.08e-06	0.000299	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—TGFB1—osteoporosis	5.07e-06	0.000298	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling by GPCR—IL6—osteoporosis	4.55e-06	0.000268	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling by GPCR—IL6—osteoporosis	4.54e-06	0.000267	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling by GPCR—IL6—osteoporosis	4.49e-06	0.000264	CbGpPWpGaD
Trihexyphenidyl—CHRM4—Signaling Pathways—IL6—osteoporosis	3.99e-06	0.000235	CbGpPWpGaD
Trihexyphenidyl—CHRM5—Signaling Pathways—IL6—osteoporosis	3.82e-06	0.000225	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—MYC—osteoporosis	3.58e-06	0.00021	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—TGFB1—osteoporosis	3.57e-06	0.00021	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—MYC—osteoporosis	3.56e-06	0.00021	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—TGFB1—osteoporosis	3.56e-06	0.000209	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—MYC—osteoporosis	3.53e-06	0.000208	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—TGFB1—osteoporosis	3.52e-06	0.000207	CbGpPWpGaD
Trihexyphenidyl—CHRM1—Signaling Pathways—IL6—osteoporosis	2.69e-06	0.000158	CbGpPWpGaD
Trihexyphenidyl—CHRM3—Signaling Pathways—IL6—osteoporosis	2.68e-06	0.000158	CbGpPWpGaD
Trihexyphenidyl—CHRM2—Signaling Pathways—IL6—osteoporosis	2.65e-06	0.000156	CbGpPWpGaD
